logo
 
Bharat Biotech International Ltd said it started clinical trials of the Tuberculosis vaccine MTBVAC on adults in India. This is the first vaccine against Tuberculosis derived from a human source by the Spanish bio-pharmaceutical company, Biofabri.

The trials are carried out by Bharat Biotech in close collaboration with Biofabri, the company said. After completing a dose



escalation trial in HIV uninfected adults, a Phase2 study in HIV-infected adults has started in 2024 to determine whether MTBVAC is safe in this population. 

The companies hope that the new vaccine will be a milestone in global vaccinology and called it an example of public-private, national and international collaboration.




No Comments For This Post, Be first to write a Comment.
Leave a Comment
Name:
Email:
Comment:
Enter the code shown:


Can't read the image? click here to refresh
etemaad live tv watch now

Todays Epaper

English Weekly

neerus indian ethnic wear
Latest Urdu News

Do you think AAP will perform better in Delhi polls without alliance?

Yes
No
Can't Say